Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
June 27 2022 - 7:00AM
Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and
its wholly owned subsidiary Clene Nanomedicine, Inc., a
clinical-stage biopharmaceutical company focused on revolutionizing
the treatment of neurodegenerative disease, today announced that
Rob Etherington, the Company’s President and CEO, has been invited
to participate in the “Innovations in ALS - Exploring New
Treatments In Development” virtual panel presented by Maxim Group
LLC and hosted by M-Vest at 11 a.m. EDT on Tuesday, June 28. M-Vest
members can follow the live event live here. At the same link,
non-members can sign up.
Amyotrophic lateral sclerosis (ALS) remains a
highly debilitating and deadly neurological disease despite having
approved therapies on the market. Current therapies provide
benefits for some patients, but there remains a high unmet need for
new therapies and research into the disease. The panel discussion,
which will focus on current research and development in the field
of ALS, will be moderated by Maxim Group Senior Biotech Analyst,
Naz Rahman, CFA, and will feature Mr. Etherington along with Alon
Ben-Noon, Co-Founder and CEO of NeuroSense Therapeutics.
Focused on advancing new medicines, Clene is
currently in late-stage clinical development with its lead drug
candidate, CNM-Au8®, as a potential treatment for ALS. The Company
expects topline data in the third quarter from the
registrational Phase 2/3 HEALEY ALS Platform trial that is
evaluating CNM-Au8 in ALS patients. CNM-Au8 is an oral suspension
of gold nanocrystals developed to restore neuronal health and
function by increasing energy production and utilization. The
catalytically-active nanocrystals of CNM-Au8 drive critical
cellular energy producing reactions that enable neuroprotection and
remyelination by increasing neuronal and glial resilience to
disease-relevant stressors. CNM-Au8 is a federally registered
trademark of Clene Nanomedicine, Inc.
About Clene
Clene is a clinical-stage biopharmaceutical
company focused on revolutionizing the treatment of
neurodegenerative disease by targeting energetic failure, an
underlying cause of many neurological diseases. The company is
based in Salt Lake City, Utah, with R&D and manufacturing
operations in Maryland. For more information, please
visit www.clene.com or follow us
on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended, which are intended to be covered by the
“safe harbor” provisions created by those laws. Clene’s
forward-looking statements include, but are not limited to,
statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding our future
operations. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. These forward-looking statements
represent our views as of the date of this press release and
involve a number of judgments, risks and uncertainties. We
anticipate that subsequent events and developments will cause our
views to change. We undertake no obligation to update
forward-looking statements to reflect events or circumstances after
the date they were made, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws. Accordingly, forward-looking statements
should not be relied upon as representing our views as of any
subsequent date. As a result of a number of known and unknown risks
and uncertainties, our actual results or performance may be
materially different from those expressed or implied by these
forward-looking statements. Some factors that could cause actual
results to differ include our substantial dependence on the
successful commercialization of our drug candidates, if approved,
in the future; our ability to demonstrate the efficacy and safety
of our drug candidates; the clinical results for our drug
candidates, which may not support further development or marketing
approval; actions of regulatory agencies; our ability to achieve
commercial success for our drug candidates, if approved; our
ability to obtain additional funding for operations; the effects of
inflation; the effects of staffing and materials shortages; the
possibility that we may be adversely affected by other economic,
business, and/or competitive factors; and other risks and
uncertainties set forth in “Risk Factors” in our most recent Annual
Report on Form 10-K and any subsequent Quarterly Reports on Form
10-Q. In addition, statements that “we believe” and similar
statements reflect our beliefs and opinions on the relevant
subject. These statements are based upon information available to
us as of the date of this press release, and while we believe such
information forms a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should
not be read to indicate that we have conducted an exhaustive
inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain and you are
cautioned not to rely unduly upon these statements. All information
in this press release is as of the date of this press release. The
information contained in any website referenced herein is not, and
shall not be deemed to be, part of or incorporated into this press
release.
The information contained in any website
referenced herein is not, and shall not be deemed to be, part of or
incorporated into this press release.
Investor Contact Morgan BrownChief Financial
Officermorgan@clene.com+1-801-201-9626
Media ContactErica Fiorini, Ph.D., or David
SchullRusso Partners,
LLCErica.fiorini@russopartnersllc.comDavid.schull@russopartnersllc.com+1-212-845-4253
Clene (NASDAQ:CLNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clene (NASDAQ:CLNN)
Historical Stock Chart
From Apr 2023 to Apr 2024